PMID- 29121620
OWN - NLM
STAT- MEDLINE
DCOM- 20171128
LR  - 20171128
IS  - 1175-8716 (Electronic)
IS  - 0028-8446 (Linking)
VI  - 130
IP  - 1465
DP  - 2017 Nov 10
TI  - Dispensing patterns for antidiabetic agents in New Zealand: are the guidelines 
      being followed?
PG  - 12-18
AB  - AIMS: Type 2 diabetes mellitus (T2DM) is a significant public health issue in New 
      Zealand. Effective management and glycaemic control is critical for reducing 
      diabetes-related complications. Treatment guidelines are well established in New 
      Zealand. Using dispensing data as a proxy for prescribing data, this paper aims 
      to describe the pattern of first- and second-line antidiabetic agent (AA) 
      dispensing for T2DM in New Zealand and assess adherence with treatment 
      guidelines. METHODS: Analysis of national dispensing data for AA medications 
      using the Pharmaceutical Collection database from 2007/08 to 2015/16. RESULTS: 
      Metformin monotherapy remains the most commonly prescribed first-line T2DM 
      medication prescribed, accounting for 85% of initial agents prescribed. 
      Sulfonylureas are the most common second-line agents used, accounting for 70% of 
      all second-line agents. CONCLUSION: There is a high degree of adherence with the 
      T2DM treatment guidelines in New Zealand.
FAU - Murray, Peter
AU  - Murray P
AD  - Medical Directorate, PHARMAC, Wellington.
FAU - Norris, Hew
AU  - Norris H
AD  - Analysis, Corporate Directorate, PHARMAC, Wellington.
FAU - Metcalfe, Scott
AU  - Metcalfe S
AD  - Medical Directorate, PHARMAC, Wellington.
FAU - Betty, Bryan
AU  - Betty B
AD  - Medical Directorate, PHARMAC, Wellington.
FAU - Young, Vanessa
AU  - Young V
AD  - Operations Directorate, PHARMAC, Wellington.
FAU - Locke, Bronwyn
AU  - Locke B
AD  - Engagement and Implementation Directorate, PHARMAC, Wellington.
LA  - eng
PT  - Journal Article
DEP - 20171110
PL  - New Zealand
TA  - N Z Med J
JT  - The New Zealand medical journal
JID - 0401067
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
CIN - N Z Med J. 2017 Nov 10;130(1465):9-11. PMID: 29121619
MH  - Blood Glucose
MH  - Diabetes Mellitus, Type 2/*drug therapy/epidemiology
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Medication Adherence/*statistics & numerical data
MH  - Metformin/therapeutic use
MH  - New Zealand
COIS- The authors are (or were at the time of writing) employees of PHARMAC; the views 
      expressed do not necessarily represent those of PHARMAC.
EDAT- 2017/11/10 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/10 06:00
PHST- 2017/11/10 06:00 [entrez]
PHST- 2017/11/10 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PST - epublish
SO  - N Z Med J. 2017 Nov 10;130(1465):12-18.